Alumis INC 10-Q quarterly reports

Alumis Inc. reported its first-quarter 2026 financial results, highlighting progress in its clinical-stage biopharmaceutical development and a strong cash position.

Alumis Inc. reported a reduced net loss in Q3 2025, driven by a bargain purchase gain from the ACELYRIN merger, while significantly increasing R&D and administrative expenses to advance its clinical pipeline.

Alumis Inc. reported a net income of $59.3 million for Q2 2025, driven by a significant gain from the ACELYRIN Merger, while advancing its lead product candidates envu and A-005 in clinical trials.

Alumis Inc. reports a net loss for Q1 2025 and provides updates on its merger with ACELYRIN, clinical trials, and a collaboration agreement with Kaken Pharmaceutical.

Alumis Inc. reports a net loss of $93.1 million for the third quarter of 2024, alongside significant increases in research and development expenses following its recent IPO.

Alumis Inc. reports a net loss of $106.4 million for the six months ended June 30, 2024, while advancing its clinical programs and completing its IPO.